Results 21 to 30 of about 174,708 (252)

Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity

Journal of Hematology & Oncology, 2021
Resistance to anti-cancer monoclonal antibody (mAb) therapy remains a clinical challenge. Previous work in our laboratory has shown that T cell help in the form of interleukin-2 maintains long-term NK cell viability and NK cell-mediated antibody ...
Zhaoming Wang, Chaobo Yin, Lawrence G. Lum, Andrean Simons, George J. Weiner   +4 more
doaj   +1 more source

Comparative efficiency of HIV-1-infected T cell killing by NK cells, monocytes and neutrophils.

PLoS ONE, 2013
HIV-1 infected cells are eliminated in infected individuals by a variety of cellular mechanisms, the best characterized of which are cytotoxic T cell and NK cell-mediated killing.
Adjoa Smalls-Mantey, Mark Connors, Quentin J Sattentau   +2 more
doaj   +1 more source

Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors

mAbs, 2021
Epidermal growth factor receptor (EGFR)-targeted cancer therapy such as anti-EGFR monoclonal antibodies and tyrosine kinase inhibitors have demonstrated clinical efficacy.
Susanne Wingert, Uwe Reusch, Stefan Knackmuss, Michael Kluge, Michael Damrat, Jens Pahl, Ute Schniegler-Mattox, Thomas Mueller, Ivica Fucek, Kristina Ellwanger, Michael Tesar, Torsten Haneke, Joachim Koch, Martin Treder, Wolfgang Fischer, Erich Rajkovic   +15 more
doaj   +1 more source

γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody

Haematologica, 2011
Background Anti-CD20 monoclonal antibodies are major therapeutic agents for patients with follicular lymphoma and work through complement-mediated cytotoxicity and antibody-dependent cellular cytotoxicity.
Mounia Sabrina Braza, Bernard Klein, Geneviève Fiol, Jean-François Rossi   +3 more
doaj   +1 more source

Monocytes and the 38kDa-antigen of mycobacterium tuberculosis modulate natural killer cell activity and their cytolysis directed against ovarian cancer cell lines

BMC Cancer, 2012
Background Despite strong efforts to improve clinical outcome of ovarian cancer patients by conventional and targeted immuno-based therapies, the prognosis of advanced ovarian cancer is still poor.
Gottschalk Nina, Lang Stephan, Kimmig Rainer, Singh Mahavir, Brandau Sven   +4 more
doaj   +1 more source

Antibody-Dependent Cellular Cytotoxicity (ADCC)-Mediating Antibodies Constrain Neutralizing Antibody Escape Pathway

Frontiers in Immunology, 2019
Both neutralization and antibody-dependent cellular cytotoxicity (ADCC) may be required for effective protection against HIV-1 infection. While there is extensive information on the targets of early neutralizing antibody (nAb) responses, much less is ...
Dieter Mielke, Gama Bandawe, Justin Pollara, Melissa-Rose Abrahams, Tinashe Nyanhete, Penny L. Moore, Penny L. Moore, Penny L. Moore, Penny L. Moore, Ruwayhida Thebus, Nicole L. Yates, John C. Kappes, John C. Kappes, Christina Ochsenbauer, Nigel Garrett, Nigel Garrett, Salim Abdool Karim, Salim Abdool Karim, Georgia D. Tomaras, David Montefiori, Lynn Morris, Lynn Morris, Lynn Morris, Lynn Morris, Guido Ferrari, Carolyn Williamson, Carolyn Williamson, Carolyn Williamson   +27 more
doaj   +1 more source

Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma

Journal of Hematology & Oncology, 2016
Daratumumab is a human monoclonal antibody that targets CD38, a cell surface protein that is overexpressed on multiple myeloma (MM) cells. Preclinical studies have shown that daratumumab induces MM cell death through several mechanisms, including ...
Larysa Sanchez, Yucai Wang, David S. Siegel, Michael L. Wang   +3 more
doaj   +1 more source

Antibody-Dependent Cellular Cytotoxicity and Skin Disease

Journal of Investigative Dermatology, 1985
Antibody dependent cellular cytotoxicity (ADCC) is a recently described mechanism of immunologic lysis in which cellular targets sensitized by specific antibodies are efficiently and selectively lysed by Fc receptor (FcR) bearing nonspecific effectors.
Norris, David A., Lee, Lela A.
openaire   +2 more sources

Cross-Reactive Fc-Mediated Antibody Responses to Influenza HA Stem Region in Human Sera Following Seasonal Vaccination

Vaccines
Background: Current influenza A vaccines primarily induce neutralizing antibodies targeting the variable hemagglutinin (HA) head domain, limiting their effectiveness against diverse or emerging influenza A virus (IAV) subtypes.
Ayae Nishiyama, Takuto Nogimori, Yuji Masuta, Tomoka Matsuura, Tetsuo Kase, Kyoko Kondo, Satoko Ohfuji, Yu Nakagama, Natsuko Kaku, Sachie Nakagama, Yuko Nitahara, Yoshimasa Takahashi, Hiroshi Kakeya, Yasutoshi Kido, Wakaba Fukushima, Takuya Yamamoto   +15 more
doaj   +1 more source

Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells

Frontiers in Immunology, 2020
Isatuximab is a monoclonal antibody targeting the transmembrane receptor and ectoenzyme CD38, a protein highly expressed on hematological malignant cells, including those in multiple myeloma (MM).
Chen Zhu, Zhili Song, Anlai Wang, Srimathi Srinivasan, Guang Yang, Rita Greco, Joachim Theilhaber, Elvis Shehu, Lan Wu, Zhi-Yong Yang, Wilfried Passe-Coutrin, Alain Fournier, Yu-Tzu Tai, Kenneth C. Anderson, Dmitri Wiederschain, Keith Bahjat, Francisco J. Adrián, Marielle Chiron   +17 more
doaj   +1 more source